Bioheart Inc. previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market.
http://www.biospace.com/news_story.aspx?StoryID=281245&full=1
http://www.biospace.com/news_story.aspx?StoryID=281245&full=1
No comments:
Post a Comment